The TASC Trial: Therapeutic vs Prophylactic Anticoagulation for Acute Chest Syndrome
The TASC trial represents a significant step forward by being the first phase 3 randomized controlled trial to directly compare therapeutic versus prophylactic-dose tinzaparin for managing acute chest syndrome (ACS) in adults with sickle cell disease who do not have pulmonary artery macrothrombosis. The primary finding was that using therapeutic-dose tinzaparin successfully shortened the duration of ACS when compared to receiving a standard prophylactic dose. Furthermore, this higher dosing strategy correlated with a notable reduction in opioid consumption among the patients studied. These results suggest that simply maintaining prophylaxis might be suboptimal for some patients experiencing refractory ACS.
The TASC trial represents a significant step forward by being the first phase 3 randomized controlled trial to directly compare therapeutic versus prophylactic-dose tinzaparin for managing acute chest syndrome (ACS) in adults with sickle cell disease who do not have pulmonary artery macrothrombosis. The primary finding was that using therapeutic-dose tinzaparin successfully shortened the duration of ACS when compared to receiving a standard prophylactic dose. Furthermore, this higher dosing strategy correlated with a notable reduction in opioid consumption among the patients studied. These results suggest that simply maintaining prophylaxis might be suboptimal for some patients experiencing refractory ACS.
Show moreShow less
For adults with ACS due to sickle cell disease without macrothrombosis, consider escalating anticoagulation from prophylactic to therapeutic doses if initial supportive care fails to resolve symptoms promptly. The benefit shown here is a reduction in overall illness duration and opioid use, suggesting a potential role for higher-dose therapy beyond standard guidelines. However, remember this finding is specific to tinzaparin and the absence of macrothrombosis.